Pharmacokinetics of torasemide and its metabolites in end-stage renal disease

URN to cite this document:: urn:nbn:de:bvb:355-epub-220429
DOI to cite this document:: 10.5283/epub.22042

Krämer, Bernhard K. ; Schwab, A. ; Braun, N. ; Strutz, F. ; Müller, G. A. ; Risler, T.

Preview

PDF
(285kB)

Date of publication of this fulltext: 08 Sep 2011 06:31

Alternative links to fulltext:Pubmed

Details

Preview

Export bibliographical data

Abstract

The pharmacokinetics of torasemide, a new loop diuretic, as well as its active metabolites M1 and M3, and its inactive main metabolite, M5, were studied in 12 patients with end-stage renal failure during single i.v. (n = 6) or single oral (n = 6) dosing of 200 mg torasemide, and during chronic oral treatment for 9 days (n = 12). The elimination half-life (t1/2) of torasemide was unchanged in ...